OCTP vs. FAB, APTA, IXI, VAL, EVG, PYC, GENF, BSFA, NFX, and ROQ
Should you be buying Oxford Cannabinoid Technologies stock or one of its competitors? The main competitors of Oxford Cannabinoid Technologies include Fusion Antibodies (FAB), Aptamer Group (APTA), IXICO (IXI), ValiRx (VAL), Evgen Pharma (EVG), Physiomics (PYC), Genflow Biosciences (GENF), BSF Enterprise (BSFA), Nuformix (NFX), and Roquefort Therapeutics (ROQ). These companies are all part of the "biotechnology" industry.
Oxford Cannabinoid Technologies (LON:OCTP) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
Fusion Antibodies received 54 more outperform votes than Oxford Cannabinoid Technologies when rated by MarketBeat users.
Oxford Cannabinoid Technologies has a net margin of 0.00% compared to Fusion Antibodies' net margin of -179.67%. Oxford Cannabinoid Technologies' return on equity of -86.76% beat Fusion Antibodies' return on equity.
In the previous week, Oxford Cannabinoid Technologies' average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.
Fusion Antibodies has higher revenue and earnings than Oxford Cannabinoid Technologies.
14.1% of Oxford Cannabinoid Technologies shares are owned by institutional investors. Comparatively, 24.4% of Fusion Antibodies shares are owned by institutional investors. 29.8% of Oxford Cannabinoid Technologies shares are owned by company insiders. Comparatively, 10.4% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Oxford Cannabinoid Technologies has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Fusion Antibodies has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Summary
Oxford Cannabinoid Technologies and Fusion Antibodies tied by winning 5 of the 10 factors compared between the two stocks.
Get Oxford Cannabinoid Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCTP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford Cannabinoid Technologies Competitors List
Related Companies and Tools
